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 Premature Ovarian Insufficiency (POI) is a condition diagnosed in women who experience 
cessation of menses prior to age forty (secondary amenorrhea), or never initially begin menses 
(primary amenorrhea). Both primary and secondary amenorrhea lead to infertility, and can 
increase the risk for osteoporosis and cardiovascular disease. Typically having an idiopathic 
cause, POI is diagnosed in 1% of women before age 40, and 0.1% before age 30. In this study, 
the diagnostic process of women with POI was studied through the use of a questionnaire. 
Twenty-three women with POI were recruited through Magee Womens Hospital and other sites, 
nineteen of whom were eligible for analysis. Using logistic regression analysis, factors such as 
age of diagnosis, months of cessation, and type of amenorrhea were studied to determine the role 
they play in a participant’s opinion regarding helpfulness of providers. Odds ratios of 0.87, 0.99, 
and 3.63 were calculated for each of these factors, respectively. The most striking trend was the 
difference between women with primary amenorrhea and women with secondary amenorrhea; 
the odds of a reported helpful outcome was found to be 3.63 times more likely in those with 
secondary amenorrhea than those with primary. In addition, the results showed that most women 
find their physician provider and the internet essentially equivalently helpful with respect to 
providing health-related information about POI. Studies on the diagnostic process of women 
with POI have public health significance because this condition affects 1% of the population in 
the United States. More needs to be done in terms of providing educational and emotional 
support after a diagnosis is made. As awareness is increased, referrals to genetic counselors can 
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be made. Genetic counselors are a resource that could be utilized for these patients, not only for 
educational purposes, but also for the emotional and psychosocial aspects of a POI diagnosis.  
 v 
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1.0  INTRODUCTION 
Premature Ovarian Insufficiency (POI), also known as Premature Ovarian Failure (POF), is the 
condition when women experience early menopause. Clinical presentation includes amenorrhea 
and two follicle-stimulating hormone (FSH) levels in the menopausal range. Amenorrhea is 
considered primary if there is absent menarche altogether, in contrast to secondary amenorrhea 
when there is premature depletion of follicles in the ovaries prior to 40 years old 1. The term 
secondary amenorrhea is used when menses have been absent for more than 6 months. Early 
menopause in POI patients is in contrast to the typical age of 51 in which most women 
experience menopause8. POI affects approximately 1% of women by age 401, 8. POI leads to 
infertility and menopause symptoms. Infertility is not universal however, as 5-10% of women 
with POI are able to conceive 14. POI can be identified as having a genetic cause in some women, 
yet the cause of POI remains unknown in 90% of cases14. POI occurring spontaneously can be 
part of syndrome, due to a single gene defect, or even result from a structural abnormality in the 
X chromosome. The aim of this project was to study the responses given in a questionnaire 
administered when a woman is recruited to be in an ongoing study regarding genetic causes of 
POI. The medical and emotional needs experienced during the diagnosis process were explored – 
focusing on the benefit a genetic counselor could provide.   
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2.0  BACKGROUND AND SIGNIFICANCE  
2.1 OVERVIEW 
2.1.1 Typical ovarian function  
Women have their maximum number of follicles in the ovaries around 20 weeks gestation16, 21. 
The process of atresia starts at this time. When a female is born, her oocytes have been reduced 
in number to 700,000 down from 6-7 million16. By the time she reaches puberty, a female has 
only 400,000 follicles remaining16. Monthly ovulation and continued atresia lead to few follicles 
remaining by the time menopause arrives16, 22. In a normal development scenario, a graafian 
follicle is developed in the ovary each month. It is a new secretory structure with each monthly 
cycle, arising from a microscopic primordial follicle. This continues until menopause, when 
menses permanently ceases. This results due to the depletion of functional primordial follicles. 
The typical age for menopause in most women is around age 50. If menopause occurs before age 
40, it is considered to be premature 14.  The constant oocyte atresia mentioned can lead to early 
menopause in someone who is either starting out with fewer follicles or loses them at a more 
rapid rate16. In order for normal ovarian function to proceed, two functioning X chromosomes 
are required8. 
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2.1.2 Ovarian function and clinical presentation in women with POI 
While 1 out of 100 women under age 40 are affected with POI, the numbers reduce as the upper 
age limit is decreased. 1 in 10,000 women are affected by age 20, and 1 in 1,000 women are 
affected by age 301. Primary amenorrhea presents clinically as pubertal delay and absent 
menarche, whereas women with secondary amenorrhea often have no idea they have aberrant 
ovarian function until they experience early menopause. POI presents in a similar manner to 
natural menopause, in that the women experience heat intolerance, flushes, decreased libido, 
depression and anxiety, vaginal dryness, fatigue, etc.1 Hormone levels are characteristic as well. 
Low levels of estrogen and inhibin (the gonadal hormones) are seen, along with high levels of 
LH and FSH (the gonadotropins). This is where the name “hypergonadotropic amenorrhea” 
stems from1. An FSH value of over 40IU/L is suggestive of ovarian failure. The condition can 
come on quite suddenly for some women, while others experience signs and symptoms for years 
before a diagnosis is made. Osteoporosis and heart disease are secondary health concerns for 
women with POI1.  
Ultrasound findings during the diagnosis of POI can include small ovaries, typically 
without any growing follicles. Women with POI who have ovarian cysts may have mutations in 
LHR1. These women experience secondary amenorrhea and LH serum levels that are higher than 
serum FSH; this is contrary to typical POI patients1. Karyotype and Fragile X testing are done in 
conjunction with ultrasound and hormone levels, in attempt to determine a cause for the 
amenorrhea.  Karyotype and Fragile X testing help depict if the woman has normal 
chromosomes, as abnormal chromosomes can be causal for POI in certain circumstances.  
Half of the women that present with primary amenorrhea are found to have ovarian 
dysgenesis1. Ovarian dysgenesis is determined by a pelvic ultrasound depicting absent ovaries 
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and uterine hypoplasia. Other patients may be seen with follicles under 10 mm. This is the 
typical case in patients with more normal pubertal development and FSHR mutations2. The 
hormone FSH is necessary for the initiation of follicular growth at the antral stage. In one patient 
studied, complete FSH resistance led to infertility yet numerous small follicles were present2. 
FSHR is a G protein-couple receptor, and was linked to POI after a study in Finnish families 
with primary amenorrhea.  
The women that present with secondary amenorrhea are in the majority of women with 
POI. These cases are most likely due to premature follicular depletion secondary to multiple 
factors, including a genetic predisposition and environmental exposures. 
2.1.3 Diagnosis  
The first step in confirming a diagnosis of POI in a symptomatic woman is to rule out the 
possibility of pregnancy. Other reasons for amenorrhea should be considered, including but not 
limited to excessive exercise, emotional stress, inadequate caloric intake, and chemo/radiation 
therapy. The majority of cases of secondary amenorrhea are due to polycystic ovary syndrome, 
hypothalamic amenorrhea, primary ovarian insufficiency, or hyperprolactinemia15. Women have 
karyotype testing, as well as Fragile X carrier testing, in order to determine if a potential 
chromosome problem could be the cause.  
Initial tests to be run include a physical exam, measurement of serum prolactin, FSH and 
thyrotropin levels as well as a pelvic ultrasound. Low FSH may indicate hypothalamic 
amenorrhea (caused by stress), while high FSH can indicate menopause and prompt a repeat 
sample in one month with a serum estradiol measurement at that time14.  
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To be considered for POI, women have cessation of menses prior to age 40, symptoms of 
ovarian failure, as well as FSH levels measured on two separate blood draws greater than 40 
IU/liter (i.e. menopausal levels). Symptoms of ovarian failure can include hot flashes, night 
sweats, trouble sleeping, vaginal dryness and decreased sex drive, and mood swings14.  
Testing for adrenal antibodies can also be considered in those women that have POI not 
associated with a syndrome. Indirect immunofluorescence or 21-hydroxylase 
immunoprecipitation can be used. Positive results are obtained in an estimated 4% of women that 
have POI14. In these women, there is steroidogenic cell autoimmunity with lymphocytic 
autoimmune oophoritis as the mechanism14.  
 
 
2.1.4 Management of women with POI 
“The diagnosis of primary ovarian insufficiency affects a woman’s physical and emotional well-
being, and the management of the condition should address both”14. This statement highlights a 
goal in managing women with POI. The diagnosis of POI comes with the unexpected shock of 
infertility for many women. Lowered self-esteem, depression, anxiety, lack of support and severe 
emotional distress are all more common in this population of women. An unfortunate fact is that 
while many women want emotional guidance and support, they seldom ask for such support. It 
would potentially be beneficial to ensure that sources for emotional support are discussed with 
the patient whether it be friends, family, or a mental health professional (i.e. including genetic 
counselors).  
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Hormone replacement therapy is often used in the management of POI.  Women with 
POI are at an increased risk for health conditions including osteoporosis (increased risk of 
fractures) and ischemic heart disease. A prolonged lack of estrogen is the culprit for early onset 
of osteopenia and osteoporosis in women with POI1. It is typically recommended that a 
combined (estrogen and progestin) hormone therapy regime be used for young women who have 
POI until they reach the normal age of menopause14, 16. As far as established guidelines, 
estrogen-replacement therapy is recommended by the American Society for Reproductive 
Medicine and the International Menopause Society14, 15, 17. Oral contraceptives typically have 
more steroid hormone than is needed and are thus not recommended for management purposes. 
The goal is simply for levels of physiologic replacement.  
To establish the degree of osteopenia/osteoporosis, bone mineral density test should be 
evaluated. As it is reduced in women with POI, education should be offered on ways to maintain 
bone health. Intake of calcium and vitamin D, along with weight-bearing exercise (jogging, 
walking, resistance exercises, stair climbing) are some of the strategies14, 18.  
Additional recommendations may be advised depending on the underlying cause for the 
premature menopause in the patient.  
2.1.5 Fertility concerns  
Infertility is frequently the most devastating consequence for patients with POI. Infertility is 
irreversible, and it is often discovered late in a woman’s potential child-bearing years. Some 
patients have children early, only to discover the diagnosis of POI later on. However, many 
women postpone having children, for a variety of reasons, missing the small window of 
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opportunity to naturally conceive. However, 5-10% of women are able to conceive and deliver a 
child after receiving the diagnosis of POI14.  
While various options have been tried, the only true known solution for allowing women 
with POI to have a child involves ovum donation1. This assumes there is a completely absent 
follicular reserve. There is the possibility for the woman’s own eggs to be preserved if her 
diagnosis of POI is made early enough. Other options if parenthood is desired include adoption, 
fostering, and embryo donation14.  
Some women with POI do not wish to conceive, and as mentioned above, it is possible –
though rare – to conceive with this condition. If the wish is to avoid pregnancy, contraception 
should be used whether it is the barrier method or an intrauterine device. This is an important 
discussion to have with women after being diagnosed.  
2.2 CAUSES 
2.2.1 Genetic causes  
A first step in the diagnostic process for women with POI is chromosomal analysis. This includes 
having blood drawn and a karyotype performed. X-chromosome abnormalities are responsible 
for the majority of POI cases with ovarian dysgenesis1, 23-26. Specifically, chromosomal regions 
Xq21.3-Xq27 (for POF1) and Xq13.3-q21.1 are of interest. The former has been seen in patients 
and families showing deletions in this area, while the latter has been seen in individuals with 
balanced X/autosome translocations. Several candidate genes have been identified 27-32.  
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Well-established X chromosome defects include Turner syndrome and Fragile X 
syndrome (FMR1 gene premutation). Females with Turner syndrome have only one X 
chromosome, leading to gonadal dysgenesis, short stature, and congenital lymphedema5-7. Other 
genetic causes of Turner syndrome can include duplication of the q arm in one X chromosome. 
Mosaicism can occur as well. One in 2500 women have Turner syndrome (this number would be 
higher but affected fetuses often spontaneously abort) 4. Other features can be seen in those with 
Turner syndrome, including developmental delay, congenital heart disease, hypothyroidism, and 
ocular findings such as strabismus. Turner syndrome is a known cause for POI – there are fewer 
primordial follicles in the ovaries in utero, and these follicles commit premature apoptosis and 
are no longer present at adulthood4. A smaller uterus and vagina can be seen as well, or an 
atrophic vaginal lining. Initial ovarian function is present (known due to the presence of 
gonadotropin levels that are normal for the first months of life) but does not progress4.  Hormone 
replacement therapy is typically used in these patients. Just as with women with idiopathic POI, 
spontaneous fertility is a rare event.  
In Fragile X syndrome, the full mutation results in affected males who have mental 
retardation and autism. The trinucleotide repeat occurs in the 5’ untranslated region of the FMR1 
gene. The normal repeat length of FMR1 is less than 40 repeats16. The full mutation has more 
than 200 CGG repeats16. The full mutation results after the gene is methylated and silenced16. 
The premutation, containing 60-199 repeats, is problematic.  It was discovered in the 1980s and 
1990s that females with the premutation can have early menopause (i.e. ovarian failure) 3. It was 
noted prior that POI occurs for 1% of women in the general population. That number is increased 
to 21% for women that are premutation carriers3. An additional striking figure is that women 
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who have sporadic and idiopathic POI are premutation carriers 2% of the time; moreover, 
women with the rare form of familial POI are premutation carriers 14% of the time3.  
Monogenic defects can include both those that are syndromic and those that are isolated. 
Table 1 below outlines such disorders involved1. Despite genes being identified, the phenotype 
may still vary. For example, FSHR mutations can either be associated with primary or secondary 
amenorrhea, depending on nature of the mutation1.  
Table 1: Monogenic Causes of POI 
Monogenic defect Inheritance 
Syndromic 
defects 
Congenital disorders of glycosylation Recessive 
Galactosemia  Recessive 
Blepharophimosis-ptosis-epicanthus 
inversus syndrome 
Dominant, female-limited 
Pseudohypoparathyroidism type Ia Maternal inheritance/parental 
imprinting 
Isolated 
defects 
Follicle stimulation hormone receptor 
mutations (FSHR) 
Recessive 
Luteinizing hormone receptor mutations 
(LHR) 
Recessive 
FOXL2 mutations Dominant, female-limited 
Bone morphogenetic protein 15 (BMP15) 
mutations 
Female-limited, heterozygous 
mutation 
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2.2.2 Non-genetic causes 
In most cases of POI, the cause has yet to be determined. The questionnaire used for this 
research study is part of an ongoing study that is focused on idiopathic cases of POI. Both 
sporadic and familial appearing histories are seen in idiopathic POI. Causes can include those of 
iatrogenic origin (such as radiation, surgery, chemotherapy), autoimmune, infections, etc.  
Cigarette smoke is one of the main environmental toxins known to be associated with a 
decreased age at menopause. There is a dose-dependent effect of smoking on fertility, with the 
relationship starting at half a pack per day16.  A component of cigarette smoke called dimethyl 
benzantracene binds the aromatic hydrocarbon receptor on oocytes and granulosa cells. Nicotine 
inhibits aromatase which results in lowered oestradiol production16. Several studies have found 
similar results where female smokers have lower endogenous estrogen levels when compared to 
non-smokers19. History of cigarette smoking is therefore something that should certainly be 
asked of women who are experiencing early menopause.  
An association is seen with menopausal age among FMR1 premutation carriers and 
cigarette smoking33. It has been noted prior that premutation carriers are at risk for premature 
menopause, and later studies show smoking leads to an even earlier age of menopause among 
this group of women. A hazard ratio of 1.34 was determined from the study, indicating smoking 
indicates a risk factor for reducing the age of menopause. A cohort of 1,068 women was 
studied33.  
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2.2.3 Mechanisms of POI 
As discussed above, causes can be both genetic and non-genetic. The mechanism by which POI 
can occur can be divided into two categories. The first is follicle dysfunction. In this instance, 
follicles are in the ovary but do not have normal function. A pathologic process is preventing 
folliculogenesis to progress and follicles arrest their development. Examples include FSH-
receptor mutations, LH-receptor mutations, G-protein mutations, enzyme deficiencies, 
autoimmune lymphocytic oophoritis, and insufficient follicle number14.  
The second mechanism is follicle depletion. In this instance, primordial follicles in the 
ovary are significantly diminished. It is possible there was never an adequate amount of 
primordial follicles in utero initially, or there was an accelerated rate at which follicles were 
expended, or even a destruction of follicles via an autoimmune disease or toxic exposure. 
Examples include Blepharophimosis-ptosis-epicanthus inversus syndrome, Turner syndrome, 
and exposure to cleaning solvents such as industrial 2-bromopropane14.  
2.3 PSYCHOSOCIAL CONSIDERATIONS 
2.3.1 Depression in women with POI 
As found with several medical conditions, “POI is associated with an increased lifetime risk for 
major depression”9. One study at the National Institutes of Health Clinical Research Center 
found that women with POI have depression more often than women with Turner syndrome. The 
percentages determined were 54.5% and 36%, respectively9, 10.  The onset of depression was 
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typically found to be before the diagnosis of POI, but after menstrual irregularity had begun. 
Since women with Turner syndrome endure a longer duration of ovarian insufficiency yet tend to 
have lower depression rates, there must be additional factors contributing to the relationship 
between POI and depression besides the ovarian failure alone9. One of those factors may be the 
age at which the diagnosis is learned. For example, women with Turner syndrome often learn of 
this diagnosis at a young age in a supportive environment, compared to women with POI who 
are often diagnosed as a result of their inability to conceive9. The second scenario may have 
more emotions involved and less potential support/options.  
Studies have been conducted that look at women with POI and Axis I disorders, disorders 
that include depression, anxiety, mood, etc. to determine a correlation. The subject population 
included women with spontaneous POI, and normal female karyotypes of 46,XX. While Axis I 
disorders have a lifetime prevalence of 50% in community-based studies, a lifetime prevalence 
of 69.5% was found in women with POI9, 11. Rates specific to depression were also found to be 
higher in those with POI. Specifically, major depression had a lifetime occurrence of 54.5% in 
women with POI compared with 20% in women without POI9, 11.  
In regards to the timing of onset, 68.4% of the women – in the study described above 
who reported at least one major depression – reported that the onset was before being diagnosed 
with POI9. This is by far the majority of women in the study. However, when menstrual cycle 
irregularity (MCI) was taken into account, it was found that the women reporting at least one 
episode of major depression typically had MCI before the onset of depression. While 26.4% 
reported depression before the onset of MCI, 73.6% reported depression after the onset of MCI9. 
It was concluded that depression and POI are linked, with the menstrual irregularity (and thus 
depression) usually preceding a diagnosis of POI.  Timing varies from woman to woman, 
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shedding light on possible reasons for the variation of depression. Depression in women with 
POI can stem from several sources, including the knowledge of infertility and her role possibly 
changing within the family. Menstrual irregularity can be a significant stressor for some women, 
as well as the menopause symptoms that are paired with POI.  
2.4 ROLE OF GENETIC COUNSELING 
2.4.1 Genetic Counseling for POI with Genetic Etiology  
Genetic counseling can play an important role when POI is due to a known genetic syndrome. 
For example, if the cause for a woman’s POI is determined to be Fragile X syndrome, the genetic 
issues are broader than just POI. Fragile X syndrome is caused by expansion of CGG repeat in 
the FMR1 gene located at Xq27.3. Not only are the women at risk for POI, but there is 
intellectual disability in the affected males1’s 8. This condition is X-linked. Families would 
benefit from speaking with a genetic counselor, who could address issues such as inheritance, 
who is at risk in the family, medical implications for those affected, and genetic testing.   
Fragile X syndrome has a phenomenon known as expansion. The repeat number can 
grow, or expand, upon transmission to the fetus through a female premutation carrier16. A female 
premutation carrier would thus be at risk to have a son with Fragile X syndrome, and should be 
appropriately counseled. When the premutation is passed through the father, the length remains 
stable or contracts16. Fragile X syndrome is a complex genetic disorder, and families could 
benefit from the expertise of a genetic counseling professional.  
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There are additional circumstances where POI has a genetic etiology, as mentioned in the 
section Genetic Causes of POI. Different defects can have varying patterns of inheritance and 
different concerns that may need to be addressed. A genetic counselor would be able to explain 
the different risks associated depending on the genetic cause, and what other features may be 
associated with the condition.  
2.4.2 Familial POI and Implications for family members  
As with several conditions, a POI diagnosis of one person can have implications on the medical 
histories of other family members who may be unaware that they are carriers or possibly 
affected. If familial POI is established, early menopause can be predicted and watched for in 
other female relatives. This creates the opportunity for discussion regarding reproductive choices 
such as having children earlier or freezing embryos for the future.  
Not only can measures be taken in regards to fertility, but for other areas that POI affects 
as well. The heart and bones are important body systems to include in management. Women with 
POI should be offered symptom management, emotional support, and risk reduction strategies as 
early as possible in order to maximize benefits1. To date, overall ways a genetic counselor could 
benefit a patient with POI could not be found in the literature. Research has mainly examined 
how POI is inherited; genetic counselors can play a role in educating families about the 
inheritance of POI.   
The familial form of POI is considered to be rare. The exact figures are unknown, but the 
familial form is estimated to be responsible for 4-31% of all POI cases1. Inheritance patterns can 
vary, including autosomal dominant sex-limited and x-linked, with some families showing 
reduced penetrance. A genetic counselor would be able to assess the family history in order to 
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determine which inheritance pattern is most likely. Once this information is known, which 
females might be at risk could be better understood. For those families where only one female is 
affected and the case appears to be sporadically occurring, her female relatives could be quoted 
to be at the general population risk for developing POI1.  
 
2.4.3 Advocacy for the patient  
In regards to medical care, a genetic counselor could ensure that the patient with POI was getting 
all of the surveillance and resources she needs. Hormone replacement therapy, monitoring of 
osteoporosis and heart disease, as well as fertility concerns are all areas in which the patient may 
need an advocate and/or referral. Patients, no matter the condition in question, are not always 
aware of what management guidelines they should be following. This is seen in every area of 
genetic counseling. Genetic counseling could be a valuable resource to patients with POI, 
providing a service that offers patients both the emotional and medical support they need.  
Mental health is an additional, and very important, area that often needs to be addressed. 
Depression is not always a main discussion point, yet it should be as it is under-diagnosed and 
undertreated9. An estimated 40% of individuals with major depression do not receive any form 
of treatment9, 13. While that number is not specific to those with POI, it certainly sheds light on 
the fact that mental health is not advocated for as needed in this country. Similar research found 
6-8 years can pass before a depressed individual receives medical help9, 14.  
Depression and general infertility is a topic that has been studied in the literature. 
Infertility is estimated to affect 10-15% of couples that are of reproductive age35. The loss of 
fertility can result in several emotions including anger, depression, marital problems, anxiety, 
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social isolation, and sexual dysfunction. Diminished self-esteem, stigma and sense of loss have 
also been described for these couples35. These are areas where a genetic counselor could help 
ensure the patient has access to resources, whether it is a support group or a referral to a mental 
health specialist.  
The psychosocial issues present may reflect not only those present in a patient with POI, 
but also in her partner or family members. If a patient was having difficulty communicating with 
her family, a genetic counselor could aid in this process. Ways in which a genetic counselor 
could make a difference include helping the patient think about ways to start the conversation 
with family, role play exercises, writing family letters the patient could distribute, and prepare 
for the different reactions family members might have. There are many ways to be an advocate 
for psychosocial concerns, and a genetic counselor is trained to serve in that role.  
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3.0  MATERIALS AND METHODS  
3.1 SPECIFIC AIMS 
Aim 1: To administer a questionnaire to women recruited to be a research study regarding 
genetic causes in women with idiopathic POI.  
 
Aim 2: To study the responses in the diagnosis of POI section of the questionnaire to determine 
if a factor is present that has significant impact on a woman’s response to if she feels providers 
are helpful at the time of diagnosis.  
 
Aim 3: To demonstrate the need for an increased awareness of POI among primary care 
physicians.  
3.2 RECRUITMENT 
The recruitment of participants for this study was approved by the University of Pittsburgh 
Institutional Review Board (IRB) (PRO09080427). The most recent letter of approval can be 
found in Appendix C. Three groups of patients were enrolled in the study: (1) the subject in 
whom Premature Ovarian Insufficiency has been diagnosed, (2) family members of the subject 
 17 
with POI, and (3) healthy fertile women to be used as controls. For the purposes of this project, 
only those in the first group were focused on. Subjects were identified through routine clinical 
evaluation for female fertility in the Reproductive Endocrinology and Infertility clinic at Magee 
Womens Hospital in Pittsburgh, PA. Subjects were also referred to Magee by physicians at 
Children’s Hospital of Pittsburgh. Additional recruiting was made through The International 
Premature Ovarian Failure Association website (pofsupport.org), where interested and eligible 
women emailed the study coordinator and a blood kit was mailed to them to have their blood 
drawn and sent back to Pittsburgh. One family was recruited through the NIH. Nuclear family 
members were asked to participate at the time of the subject’s recruiting, with the primary focus 
being on the subject’s parents and unaffected sisters, if any. Controls were recruited through the 
Midlife Center, also at Magee Womens Hospital. All participation was voluntary.  
Inclusion criteria included cessation of menses prior to age 40, symptoms of ovarian 
failure (hot flashes, etc.), FSH levels measured on two separate occasions that are greater than 40 
IU/liter, unclear etiology for their POI, and normal karyotype. Exclusion criteria included those 
women with premature menopause due to surgery or known exposure to radiation and 
chemotherapy. Inclusion criteria for the control women included natural menopause after age 46, 
and at least one liveborn child.  
When recruited, the participant filled out an informed consent form (see Appendix A), 
signed a medical records release such that her medical records related to her diagnosis of POI 
could be accessed, a family history was taken, and her blood drawn. Lastly, the subject filled out 
a questionnaire (see Appendix B). Part of the questionnaire is designed to ascertain the 
diagnostic process for females with POI. The questions in this section ask if it took a lot of time 
and/or providers before a diagnosis was made and the information known and/or presented to 
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them regarding POI. The data generated from this section of the questionnaire are the focus of 
this study.  
3.3 ANALYSIS OF QUESTIONNAIRE  
Analysis was performed using questionnaire data to examine whether certain factors influenced 
the question dealing with if the women felt providers are aware of POI and helpful in the 
diagnostic process. Factors studied included the age at which the woman was diagnosed, the type 
of amenorrhea, and the number of months of menses cessation before a diagnosis was made.   
Preliminary analysis included verifying that no bias was introduced to the data. Women 
were mainly recruited through the Magee clinic, but an additional few were also recruited 
through the aforementioned POI website as well as the NIH. To check for potential biases in the 
factors listed by recruitment type, t tests and tests of proportions were calculated. To assess 
whether the means of two groups were statistically different from one another, as with the age of 
diagnosis and months cessation, a t-test was used. To assess categorical data, as with the type of 
amenorrhea and the variable of interest (if the provider was helpful), a test of proportions was 
used. If the woman said the provider was helpful, her response was scored as a 1. If the woman 
said the provider was unhelpful, was neutral in her response, or left the question blank, her 
response was scored as a 0. Four women were removed from this set of calculations. Two (ID-17 
and ID-28) were removed because they had a sister who had been previously diagnosed with POI 
and thus her diagnostic experience would be quite different from someone who is an isolated 
family member. The other two were removed (ID-29 and ID-31) because they were never 
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officially diagnosed with POI, but rather reported early menopause after her 
daughters/granddaughters were diagnosed.  
Once it was confirmed no bias was present, logistic regression analysis was performed. 
The predictor variable was if the provider was reported helpful. The variables to be factored in 
included the age of diagnosis, months cessation, and type of amenorrhea (primary vs. 
secondary). A p-value was determined for each factor, and if significant, would lead to the 
conclusion that there was an effect of that factor on the predictor variable. Odds ratios were 
calculated for each factor as well, to determine if trends are present.    
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4.0  RESULTS  
Table 2 shown below depicts a summary of the questionnaire responses in the diagnosis section. 
A total of twenty-three women were recruited (table 2), although not all were included in all 
calculations (tables 3 and 4). Please see Appendix B for a copy of the questionnaire.  
 
Table 2: Diagnosis Section of Questionnaire – Complete Version  
Subject 
with POI 
identifier 
Type 
of 
Amen. 
Age of 
diagnosis 
Type of 
provider who 
made diagnosis 
Time menses 
had stopped 
before seen by 
provider and 
diagnosed 
Number of 
providers seen 
before diagnosis 
made  
Are most 
providers aware 
of POI and/or 
helpful in 
providing 
information 
Been told a 
reason why 
have POI 
PPOF-1 2° 36 Reproductive 
endocrinologist 
3 months 2 (OB/GYN 
referred to 
endocrinologist) 
- Pre-
menopausal 
PPOF-2 1° 16 Reproductive 
endocrinologist 
n/a 4 No; some have 
been more 
knowledgeable 
than others 
Not 
specifically; 
something with 
malformation 
of the ovaries 
PPOF-5 2° 27 Primary 
physician 
4 months No. she was just 
testing my 
thyroid and one 
of the hormone 
levels told her I 
was going 
through 
menopause 
Yes. She wanted 
me to have 
genetic testing so 
felt she very 
helpful 
No  
PPOF-6 2° 30 OB/GYN Never stopped did not go to 
several providers 
before dx made 
- - 
PPOF-8 1° 17 Reproductive 
endocrinologist  
4 years 2: PCP and 
OB/GYN. No 
tests were done, 
told was a late 
bloomer 
No. I think age 
plays a role and 
also at age 13 I 
began having 
migraines w/ 
aura. This should 
I’m also Triple 
XXX and was 
told at a study 
at NIH that this 
could be a 
factor 
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have been an 
indicator 
something was 
wrong.  
PPOF-9 2° 18 OB/GYN 1 year 3 or 4 No, not then, 
maybe presently 
they are more 
familiar, but my 
OB/GYN had to 
consult several 
specialists 
Possibly 
autoimmune 
disorder  
PPOF-10 2° 22 Endocrinologist 11 months 2 Yes No 
PPOF-14 1° 16 OB/GYN and 
genetics 
specialist 
n/a 3 Just found out Just now 
PPOF-15 2° 33 General 
endocrinologist 
Approximately 
18 months 
I saw my normal 
OB/GYN who 
didn’t really 
know why it 
stopped, then 
saw an 
endocrinologist 
3x over 9 month 
period. He ran a 
few tests and 
wanted to 
monitor my FSH 
and LH levels 
before making a 
dx 
I don’t think 
normal providers 
are (obviously, 
endocrinologists 
have a little more 
experience with 
it). My OB/GYN 
recommended 
putting me on 
pills that would 
cause me to 
menstruate, but 
didn’t seem 
concerned or 
knowledgeable 
about why I 
stopped in the 
first place.  
No, but at one 
point, the 
endocrinologist 
told me its 
sometimes 
caused by 
autoimmune 
disorders. 
Within the last 
2 months, I 
have been dx 
with lichen 
plantis (in my 
mouth), which 
I think is an 
autoimmune 
disorder so I 
(not the 
doctors) 
wonder if it is 
related.  
PPOF-16 1° 15 OB/GYN n/a Yes, 2 Yes they are 
aware, and 
inform treatment 
options 
No 
PPOF-17 1° 11 POF investigator 
in Bethesda 
n/a No Since her sister 
has POF and she 
was seen by POF 
investigator, we 
went directly 
with him and he 
made the dx 
No 
PPOF-21 2° 17 Reproductive 
endocrinologist 
Less than 1 year No  OB/GYN 
providers, yes 
No 
PPOF-24 2° 27 OB/GYN, 
fertility and 
reproductive 
endocrinologist 
5 or 6 months 2 No. I went to an 
OB/GYN for 
regular pap. 
Nurses were 
completely 
unaware of POF 
Deletion on X 
chromosome 
Table 2: Continued 
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and doctor did 
not know much. 
PPOF-27 2° 34 OB/GYN, 
reproductive 
endocrinologist 
1 month 3 or 4 No. The first 
doctor was able 
to dx but 
unaware of 
additional info. 
Referred to 
reproductive 
endocrinologist 
who was helpful 
- 
PPOF-36 2° 23 Reproductive 
endocrinologist 
n/a No, but 
afterwards I saw 
4-5 different 
doctors due to 
differences in 
treatment 
Some are, some 
aren’t 
No, but it 
probably has 
something to 
do with 
genetics. 
PPOF-28 2° 26 Reproductive 
endocrinologist 
Hadn’t stopped 
completely; was 
seen for 
menopause-like 
symptoms  
2: one 
reproductive 
endocrinologist 
and one 
gynecologist 
OBs are aware I 
think but I don’t 
think they push 
for early 
detection as 
much as they 
should. I think if 
the chance is 
there, girls 
should be 
encouraged to get 
oocyte 
preservation as 
soon as possible 
I was told that 
no one knew 
why, it could 
be a fluke 
PPOF-29 2° Never 
officially 
diagnosed 
OB/GYN - - No. My doctor 
did not believe 
me when I started 
with menopause 
symptoms – told 
me I was too 
young. He was 
also extremely 
hesitant to dx my 
daughter 
- 
PPOF-31 2° Never 
officially 
diagnosed 
PPOF-34 2° 37 OB/GYN 2.5 years Yes, 2 other 
OB/GYN, 2 
PCPs 
No, the other 
OB/GYNs never 
mentioned the 
possibility or did 
testing. PCP 
ordered the blood 
work and told me 
it was menopause 
No 
PPOF-37 2° 39 Reproductive 
endocrinologist 
4-5 months 2 No, they keep 
thinking I am 
pre-menopausal. 
No 
Table 2: Continued 
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They tell me they 
don’t understand 
how to manage it 
and defer 
management to 
the reproductive 
endocrinologist 
PPOF-39 1° 16 Medical 
endocrinologist 
n/a No Very rare, so no No, possible 
genetics 
PPOF-40 2° 18 Reproductive 
endocrinologist 
4-5 months No - No 
PPOF-42 2° 17 Internist 
followed by 
endocrinologist 
and OB/GYN 
About 4 months No I was lucky my 
pediatrician was 
educated but no, 
not enough know 
especially about 
treatment 
options. There 
needs to be better 
advice on 
preventative 
measures for 
future health 
related problems.  
No, I wish 
 
“-” symbolizes that the person left question blank in the questionnaire  
n/a for “time menses had stopped before seen by provider and diagnosed” if primary amenorrhea  
 
Table 3 below depicts the four participants from Table 2 who were removed, leaving a new total 
of 19 women.  
Table 3: Participants Removed before Analysis 
POI ID Reason Participant was Removed from Analysis 
17 Had sister who had been previously diagnosed with 
POI (diagnostic experience would be different in 
comparison to someone who has not had family 
member diagnosed with POI before them) 
28 Had sister who had been previously diagnosed with 
POI (diagnostic experience would be different in 
comparison to someone who has not had family 
member diagnosed with POI before them) 
29 Not officially diagnosed with POI 
31 Not officially diagnosed with POI 
 
Table 2: Continued 
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Table 4 below depicts the data to be used in the logistic regression analysis.  
 
Table 4: Diagnosis Section of Questionnaire - Data to be used for Analysis 
POI ID 
number  
How 
Recruited 
Age of 
Diagnosis 
Type of 
Amen. 
Months Cessation 
before Diagnosis 
If Provider Helpful 
(1=yes; 0=no, 
neutral, blank) 
1 Magee 36 2° 3 0 
2 Magee 16 1 0 0 
5 Magee  27 2 4 1 
6  Magee 30 2 0 0 
8  Magee 17 1 48 0 
9 Magee 18 2 12 0 
10 Magee 22 2 11 1 
14 Magee 16 1 0 0 
15 Magee 33 2 18 0 
16 NIH 15 1 0 1 
21 Magee 17 2 11 1 
24 Website 27 2 5.5 0 
27 Magee 34 2 1 0 
36 Magee 23 2 0 0 
34 Website 37 2 30 0 
37 Magee 39 2 4.5 0 
39 Magee 16 1 0 0 
40 Magee 18 2 4.5 0 
42 Website 17 2 4 0 
TOTALS Magee: 
 15 women 
 
Other:  
4 women  
Magee:  
Mean of 
24.13 yrs 
 
Other:  
Mean of  
24 yrs 
Magee:  
4 with 1°, 
11 with 2° 
 
Other:  
1 with1°, 
3 with 2° 
Magee:  
Mean of  
7.8 months 
 
Other:  
Mean of 
9.9 months 
Magee:  
3 with “1” (helpful) 
12 with “0” 
 
Other:  
1 with “1” (helpful)  
3 with “0” 
  
A preliminary analysis was conducted to confirm that location of recruitment did not introduce 
bias into the data. The following summarizes this analysis:  
Age of diagnosis had a t-value of 0.027490316022591624. The probability of this result, 
assuming the null hypothesis (that there is not a statistical difference between the 2 
groups recruited on average), is 0.98.  
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Months cessation had a t-value of -0.291. The probability of this result, assuming the null 
hypothesis, is 0.77.  
Type of amenorrhea: Determined at 95% confidence that there is not a significant 
difference between the two observed proportions. Of the 15 women recruited through 
Magee, 26.67% had primary amenorrhea. Of the 4 women recruited through “other” (i.e. 
NIH or the POF website), 25% had primary amenorrhea.  
Reported provider being helpful: Determined at 95% confidence that there is not a 
significant difference between the two observed proportions. Of the 15 women recruited 
through Magee, 20% reported her provider being helpful. Of the 4 women recruited 
through “other” (i.e. NIH or the POF website), 25% reported her provider not being 
helpful or gave a neutral response.  
 
 
Logistic Regression Analysis lists whether the participant reported the provider being helpful as 
the variable of interest. Each factor is also listed (age of diagnosis, type of amenorrhea, months 
cessation) with a β that represents the associated odds ratio.  
 (provider helpful) = (age of diagnosis)β + (type of amenorrhea)β + (months cessation)β 
 
Table 5: Results of Logistic Regression Analysis 
Factor/Variable Average P-value (less than 
0.05 as significant) 
Odds Ratio 
(β) 
Age of diagnosis (yrs) 24.1053 0.2176 0.8722 
Type of Amenorrhea 1.7368 0.4004 3.6262 
Months Cessation 8.2368 0.8287 0.9868 
 
No p-values were found to be significant. 
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Table 6 lists the type of resource from which the recruited women felt they learned the most 
about POI. The percentage of each type of resource is shown in figure 1.   
 
Table 6: Responses Regarding Education of POI 
 Where learned the most about Premature Ovarian Failure: 
Subject with 
POI 
identifier 
Physician 
provider 
Internet POF support 
group in 
local area 
Medical 
library 
Research 
study 
Other 
PPOF-1 X X     
PPOF-2 X X     
PPOF-5      REI clinic 
at Magee 
PPOF-6 X      
PPOF-8 X X X  X  
PPOF-9 X      
PPOF-10 X X     
PPOF-14 X      
PPOF-15  X     
PPOF-16 X      
PPOF-17     POF investigator  
PPOF-21 X      
PPOF-24  X     
PPOF-27 X      
PPOF-36  X    X 
PPOF-28 X X     
PPOF-29  X     
PPOF-31 No response 
PPOF-34 X X     
PPOF-37 X X     
PPOF-39 X      
PPOF-40 X X   X  
PPOF-41  X     
TOTALS 15 13 1 0 3 3 
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37%
9%
9%
3%
Physician
Provider
Internet
POF Support
Group
Medical Library
Research Study
Other
 
Figure 1: Pie Chart of the Reported Education of POI 
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5.0  DISCUSSION  
5.1 ANALYSIS OF QUESTIONNAIRE 
The data from the logistic regression analysis is presented in Table 5 of the results section. Three 
variables were studied to determine if they influenced a woman’s answer to the question of 
whether her provider was helpful during her diagnosis and provided her with information about 
POI and treatment. The factors studied were the age of diagnosis, the type of amenorrhea 
(primary vs. secondary), and the months cessation for her menses before a diagnosis was made. 
Prior to the regression analysis, it was determined that bias was not introduced based on the 
recruitment site – participants were recruited through Magee and recruited outside Magee 
(through either NIH or the POF website).  
 After the regression analysis, no p-values were found to be significant for any of the three 
variables. It can thus not be concluded, at a statistically significant level, that these variables 
have an effect on the outcome of whether the woman thought the provider was helpful. However, 
trends were seen in the odds ratio values. In regards to the age of diagnosis, the odds ratio was 
0.8722. This indicates this factor is associated with slightly lower odds of the participant finding 
her provider helpful. As the age of women increases, the rated helpfulness decreases slightly. 
This could be due to a variety of reasons, including older women having higher expectations for 
providers, and there being less options available regarding having children.   
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 In regards to the months of cessation before a diagnosis was made, the odds ratio was 
0.9868. The value is very close to 1, indicating this factor likely does not play a major role 
affecting the odds of the outcome (if the provider was reported helpful).  
 Finally, with regards to the type of amenorrhea, an odds ratio of 3.6262 was calculated. 
This variable has the most significant trend of all three variables studied. With an odds ratio of 
over 1, the type of amenorrhea is associated with higher odds of the participant feeling the 
provider was helpful. Specifically, the odds of the helpful outcome was found to be 3.6262 times 
more likely in those with secondary amenorrhea compared to those with primary amenorrhea. 
More fertility options exist for those with secondary amenorrhea in comparison to those with 
primary amenorrhea.  
The second main analysis examined where each woman recruited felt that she learned the 
most about Premature Ovarian Failure (table 6). Fifteen women learned the most from her 
physician provider, thirteen from the internet, one from a POI support group in her local area, 
none from a medical library, three from a research study, and three from “other.” It is interesting 
that the numbers for physician provider and the internet were almost equivalent. Research from 
the Pew Research Center published a survey from September 2012 that reported 72% of internet 
users report looking online for health information within the last year34. Most (77%) start their 
search at a search engine, while only 13% of online health users start at a website specializing in 
health information34. These results highlight some interesting points. Physicians should be made 
more aware of POI, including the emotional and psychosocial issues that women often 
experience with POI. Physicians should be prepared to refer their patients to a genetic counselor 
or other appropriate health care providers who can serve as an advocate, and determine if there 
are implications for other family members. It could also be suggested that medical staff should 
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provide internet references and sources to their patients – such that patients are using reliable 
sources to build their knowledge base.  
Few women reported learning much from support groups, medical libraries, research 
studies, and other sources. Perhaps these areas could be explored and publicized more to 
patients. A genetic counselor would be knowledgeable in these areas and be able to direct 
patients to such sources. Knowledge coming from a variety of places is often the most helpful, 
and would allow patients to tailor their needs by having more resources and options available to 
them.  
5.2 ADDITIONAL TRENDS SEEN IN THE QUESTIONNAIRE  
Additional trends noted include the presence of cigarette smoking in a few of the participants. As 
mentioned in the Background and Significance section, cigarette smoking is a known 
environmental toxin that can lead to a decreased age of menopause16. Participants with ID 
numbers 5, 24, 31, 34, and 37 all have a history of smoking. The range varied from considering 
themselves a “social smoker” (i.e. smoking when they drink) to smoking every day for 42 years. 
All of those who noted a smoking history on their questionnaire had secondary amenorrhea. This 
is interesting, as their smoking history could certainly be a factor as to why they have POI.  
Other information of note includes a history of depression in women with ID numbers 1 
and 28. Additionally, subject ID number 8 noted that she “did not receive emotional support.” 
Women diagnosed with POI who are experiencing depression could benefit (and desire) 
psychological support. A genetic counselor could either be that source of support, or provide a 
referral if necessary.  
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Some of the women recruited had a family history of POI. Whether or not the specific 
genetic cause can be identified, a genetic counselor could work with these types of families to 
help them understand whether there may be an underlying genetic cause. In one of the families, 
two sisters (ID numbers 16 and 17) both had primary amenorrhea and were diagnosed with POI. 
In another family, there was a history of POI in 2 sisters, their mother, and their maternal 
grandmother. While the mother and maternal grandmother were never officially diagnosed, this 
family appears to show a dominant inheritance pattern for early menopause. While POI is 
isolated in many families, there is certainly evidence to support a genetic cause in other families. 
A genetic counselor would be an appropriate health care provider to determine which families 
might fall into which category.  
A final interesting trend noted was the reproductive history of several participants. One 
woman (ID number 10) shared that she has delivered a baby since being diagnosed with POI. 
This is a rare example of the statistic that 5-10% of women with POI are able to conceive 14. 
Another, ID number 27, had three children before being diagnosed. This is evidence in support 
of women who are diagnosed later in life after they have already had children. This is pointed out 
in support of the fact that a genetic counselor could help the patient talk to her family about 
timing of family planning. If other women are at risk of POI, then they could benefit from such 
knowledge as they would be able to consider starting their family sooner.  
5.3 LIMITATIONS OF STUDY AND FUTURE DIRECTIONS 
There are several limitations to the current study. First, only twenty-three women with POI were 
recruited, and only nineteen of these women were eligible for the analysis portion. Few eligible 
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women were seen though the Magee REI clinic, and those that were seen did not always agree to 
participate. A larger sample size would have increased the likelihood of obtaining statistically 
significant data, and further conclusions could have been made. For those women that were 
successfully recruited, not all of them fully completed the questionnaire. This limited the 
strength of the calculations. To improve this aspect of the study, participants could be 
encouraged to take the questionnaire home if having more time would allow them to completely 
fill it out.  
Future directions for the study could include gathering more women who have POI to 
participate in the study. With more women recruited, there would be more questionnaires 
available for analysis of trends and conclusions. Other future studies may include adding 
questions to the questionnaire to have more specific data in regards to the genetic and genetic 
counseling aspect of POI. It could be asked if women would be interested in genetic counseling, 
and ways they feel they would benefit from having a genetic counselor as an advocate and 
resource.   
5.4 PUBLIC HEALTH SIGNIFICANCE 
Premature Ovarian Insufficiency affects 1% of women by age 401, 8. POI can come as an 
emotionally stressful diagnosis for women, and it can have implications for more than just 
fertility. Osteoporosis and cardiovascular disease are increased risks for women with POI. Thus, 
three conditions – infertility, osteoporosis, and cardiovascular disease – are intertwined in one 
diagnosis. Over time, it is expected that more will be learned about this public health issue and 
the diagnosis recognized earlier. This has potential to diminish the diagnostic odyssey. With 
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better education, women can reduce their risk for the co-morbid conditions and improve the 
likelihood of having children. Depression is a major concern with POI as discussed, and as a 
public health issue, it should be an important component of management options.  
Not only can POI be devastating for the patient, but to her family as well. While the 
majority of POI is idiopathic, or due to an unknown cause, 4-31% of cases are thought to be 
familial1. Having an explanation for the diagnosis, whether it be inherited or not, can serve as a 
consolation to patients and families. Other family members can be educated about what their 
risks are for POI, and couples can be informed with regards to their options for family planning 
and recurrence risk. Genetic counselors are an appropriate advocate in this regard – not only can 
genetic counselors provide resources and explanations, but help the family work through who 
might be at risk and educate at risk members about various medical management options. 
Additionally, better technology may allow for improved detection. Family planning is one of the 
main concerns for couples and families, and earlier detection often allows for greater 
reproductive options.  
5.5 CONCLUSIONS   
The diagnostic process of women with Premature Ovarian Insufficiency was studied, specifically 
in regards to if they thought their provider was helpful during this process. Her age of diagnosis, 
type of amenorrhea, and months of cessation for her menses were examined in order to 
determine if these factors influenced a response of providers being helpful. None of the factors 
were found to be significantly associated with rated helpfulness. Odds ratios were calculated for 
each of these factors and trends were noted. As the age of diagnosis increased, the provider being 
 34 
reported as helpful was 0.87 times less likely. It can be concluded that months of cessation does 
not affect the women’s decision of whether the provider was helpful since the odds ratio was 
calculated to be so close to the value 1. The type of amenorrhea proved to be the best indicator; 
women with secondary amenorrhea were 3.62 times more likely than women with primary 
amenorrhea to feel their provider was helpful during their diagnosis. While both groups of 
women – those with primary amenorrhea and those with secondary amenorrhea – could benefit 
from seeing a genetic counselor, perhaps those with primary amenorrhea are slightly more in 
need.  
When asked where women learned the most about POI, the two most common answers 
were the internet and her physician provider. This research study suggests the lack of satisfaction 
and knowledge being gained from a provider, and it is possible to conjecture that other health 
care providers may be beneficial to this population such as a genetic counselor. Genetic 
counselors are educators, provide resources, serve as advocates, and are a source for 
psychosocial support. A genetic counselor would be able to address the genetic and emotional 
sides of a POI diagnosis, and provide information regarding medical management of POI. 
Increased awareness of POI and the value of a genetic counseling referral for women with this 
condition could help ensure that the patient is receiving the most complete care possible.  
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APPENDIX A 
POF PATIENT CONSENT FORM  
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
TITLE: Genetic Basis of Female Fertility and Premature Ovarian Failure 
University of Pittsburgh IRB # PRO09080427 
PRINCIPAL INVESTIGATOR:   Aleksandar Rajkovic, M.D. 
Magee Women’s Hospital 
300 Halket Street 
Pittsburgh, PA 15213 
Telephone: (412) – 641-4212 
rajkovic@magee.edu 
CO-INVESTIGATORS:   Joseph Sanfilippo, M.D., MBA 
Shweta Nayak, M.D. 
Judith Balk, M.D. 
SOURCE OF SUPPORT:   Department of Genetics, UPMC 
Why is this research being done? 
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Many cases of premature ovarian failure and infertility have an unknown cause. By 
studying the unique genetic makeup of women with this disease, we may gain insights into the 
disease process and in the future be able to offer better diagnostics and therapies to women with 
ovarian failure and infertility.  You are being asked to participate in a research study in which we 
will obtain a blood sample from you in order to test for certain genetic aberrations. 
Who is being asked to take part in this research study? 
You are being invited to take part in this research study because you have been diagnosed 
with unexplained Premature Ovarian Failure (POF). People invited to participate in this study 
must have a diagnosis of POF, have a family member with POF, or be a postmenopausal woman 
with at least one child.  Patients with a known cause of POF, such as surgery to remove pelvic 
organs, chemotherapy, radiation or known genetic disorders, such as Fragile X or Turner ’s 
syndrome, are excluded. 
What procedures will be performed for research purposes? 
A total of 1,160 subjects will be asked to participate in our study. You will be one of 
approximately 1,160 subjects to be asked to participate at this location. We are providing you 
with the information so you know that you are not the only one that is being asked to participate 
in the research study. The research will be conducted at the following location(s): University of 
Pittsburgh, Magee Womens Hospital. If you decide to participate, you will read and sign an 
informed consent form and return it to the study coordinator.  Once this form is received, you 
will be sent the materials related to the research study. You will provide the study doctor with 
your medical and family history, information about premature ovarian failures or other 
gynecologic problems. You will also provide the study doctor with one blood sample or a tissue 
sample, a questionnaire, and a pedigree of your family. 
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We would like to get approximately 20cc or 4 teaspoons of blood from you to possibly 
find out if the cause of ovarian failure or infertility is due to genetic changes. You can come into 
our office and have a nurse draw blood from your vein in your arm. You can also have your 
primary care physician or their nurse draw the blood and mail the sample to our office. If you 
would like to do this then we will be able to provide you with a laboratory order to have your 
primary doctor's office obtain the blood sample. Also, we will provide you with a blood 
collection kit, instruction sheet that tells you what to do with the sample once it is obtained and a 
FEDEX envelope with a pre-paid return mailer to send the sample to our office. This blood will 
be used only to get genetic material (DNA). The blood sample is for research purposes only. We 
will look at genes thought to be related to infertility and POF, but we may also look at all of the 
genes in your body, as there may be many other genes that are not known to contribute to POF 
today but may cause your POF. We may also ask you for another sample of your blood if we are 
unable to obtain an adequate DNA sample or if we find new genetic information that may be 
important to the study, and requires more DNA. 
The tissue sample will be a sample that has already been removed by a past surgery or 
biopsy. We would like to use a small amount of tissue that is not needed by the pathologist (the 
doctor that studied your tissue). We will only be examining tissue that would have otherwise 
been destroyed. Only if excess tissue from any surgical specimen is available will it be used for 
this study. No surgery will be performed solely for the purpose of obtaining surgical specimens. 
Tissue samples used for the study will only be those obtained at an earlier time for previous 
testing. If you would like to provide us with a sample of your tissue then you will need to give us 
the name of the hospital where surgery or biopsy was performed. We will also need you to 
provide us with a medical release form. The medical release form is a form that you sign that 
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grants us permission to allow us to obtain the tissue from the pathologist. 
Once we receive your blood and/or tissue specimen it will be sent to the Magee Womens 
Research Institute for analysis. Specimens will be stored in a locked freezer located in the 
principal investigator's laboratory. The specimen will be provided a case number and no personal 
information will be linked to the specimen.  The results of your DNA analysis will be entered 
into a computerized database and reviewed by the principal investigator and his staff. Only the 
study doctor and their research assistant will have access to the original research data. Data will 
be completely confidential, and will not be revealed to family members, insurance companies, 
employers, or other individuals or organizations. 
Your DNA may be analyzed in the future as new tests become available that are related 
to premature ovarian failure. The DNA will be analyzed only to search for genes (functional unit 
of hereditary material) that may cause premature ovarian failure. No additional research (i.e., 
research not related to POF) will be performed on your DNA without your written permission. 
You may revoke your authorization for DNA research analyses at any time. In addition, if any 
DNA remains, you can request that it be destroyed and discarded at any time. All aspects of this 
study will be kept strictly confidential. 
PEDIGREE CHART: You will complete a pedigree chart. A pedigree is like a family tree 
chart. It will identify family members that may have had problems with infertility or POF. We 
will give you a pedigree worksheet for you to complete. This form must be completed and 
returned to the study doctor or their coordinator. 
QUESTIONNAIRE: You will complete a brief questionnaire. The questionnaire will take 
no longer than fifteen minutes to complete. The questionnaire will ask you questions about your 
menstrual history, how you were diagnosed with POF, medical and family history. Please answer 
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the questions as completely as possible. 
FAMILY MEMBERS: We are interested in studying your family regardless of whether 
they can or cannot have children to help us find out if genetic changes are related to infertility or 
POF. We will be asking you to provide information about this study to your family members in 
order to test their DNA. We will provide you with a separate form for you to provide to them so 
they can read and possibly participate in the study. 
The duration of your participation is limited to the time necessary to obtain blood or other 
tissue, to verify diagnosis and perform lab studies. This is expected to be 3 years or less. Blood 
or tissue will be stored and tested for newly detected genes that may be identified. Your research 
doctor may be able to provide you with part of your information while the study is in progress if 
you provide a written request. Test results will be revealed to you only at the discretion of the 
study doctor. 
What are the possible risks, side effects, and discomforts of this research study? 
The possible risks of this research study are the risks associated with obtaining the blood 
sample. Bruising, soreness, or rarely, infection may occur as a result of the needle sticks to 
obtain blood from your vein. 
Questionnaire: If you are unable to give information about your family's medical history, 
it may cause anxiety. It is okay if you are able to provide us with limited information you or your 
family knows. 
Pedigree: Although the risk is minimal it may cause anxiety. 
There is a chance of breach of confidentiality associated with release of medical and 
personal information.  Certain risks are rare but can impact insurability, employability, 
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reproduction plans, or have a negative impact on family relationships or result in paternity suits 
or stigmatization. 
If you request your results of the genetic testing, there is a small risk of learning results 
which may not be accurate. There is also a small risk of uncovering genetic information that you 
did not want to know.  If you have any questions regarding these results, we will be happy to 
discuss them with you and provide genetic counseling. 
What are possible benefits from taking part in this study? 
You will receive no direct benefit from your participation in this study. However, your 
participation may help the investigators better understand genetic causes of infertility or POF. It 
is possible that your participation in this study will benefit women with POF in the future. 
What treatments or procedures are available if I decide not to take part in this research 
study? 
If you decide not to take part in this research study, you will continue to have the 
standard care for Premature Ovarian Failure. 
If I agree to take part in this research study, will I be told of any new risks that may be 
found during the course of the study? 
You will be promptly notified if, during the conduct of this research study, any new 
information develops which may cause you to change your mind about continuing to participate. 
Will my insurance provider or I be charged for the costs of any procedures performed 
as part of this research study? 
Neither you, nor your insurance provider, will be charged for the costs of any of the 
procedures performed for the purpose of this research study (i.e., the blood work).  You will be 
charged, in the standard manner, for any procedures performed for your routine medical care. 
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Will I be paid if I take part in this research study? 
Yes. Five dollars cash will be offered to you for participating in this research study. 
Who will pay if I am injured as a result of taking part in this study? 
If you believe that the research procedures have resulted in an injury to you, immediately 
contact the Principal Investigator who is listed on the first page of this form. Emergency medical 
treatment for injuries solely and directly related to your participation in this research study will 
be provided to you by the hospitals of UPMC. Your insurance provider may be billed for the 
costs of this emergency treatment, but none of those costs will be charged directly to you. If your 
research-related injury requires medical care beyond this emergency treatment, you will be 
responsible for the costs of this follow-up care. At this time, there is no plan for any additional 
financial compensation. 
Who will know about my participation in this research study? 
Any information about you obtained from this research will be kept as confidential 
(private) as possible.  All records related to your involvement in this research study will be 
stored in a locked file cabinet.  Your identity on these records will be indicated by a case number 
rather than by your name, and the information linking these case numbers with your identity will 
be kept separate from the research records.  You will not be identified by name in any 
publication of the research results. 
Will this research study involve the use or disclosure of my identifiable medical 
information? 
This research study will involve the recording of current and/or future identifiable 
medical information from your hospital and/or other (e.g., physician office) records.  The 
information that will be recorded will be limited to information concerning the diagnostic tests 
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that have been performed related to Premature Ovarian Failure, as well as any pertinent medical 
or family history. 
Who will have access to identifiable information related to my participation in this 
research study? 
In addition to the investigators listed on the first page of this authorization (consent) form 
and their research staff, the following individuals will or may have access to identifiable 
information (which may include your identifiable medical information) related to your 
participation in this research study: 
Authorized representatives of the University of Pittsburgh Research Conduct and 
Compliance Office may review your identifiable research information (which may 
include your identifiable medical information) for the purpose of monitoring the 
appropriate conduct of this research study. 
In unusual cases, the investigators may be required to release identifiable 
information (which may include your identifiable medical information) related to your 
participation in this research study in response to an order from a court of law.  If the 
investigators learn that you or someone with whom you are involved is in serious danger 
or potential harm, they will need to inform, as required by Pennsylvania law, the 
appropriate agencies. 
Authorized representatives of the UPMC hospitals or other affiliated health care 
providers may have access to identifiable information (which may include your 
identifiable medical information) related to your participation in this research study for 
the purpose of (1) fulfilling orders, made by the investigators, for hospital and health care 
services (e.g., laboratory tests, diagnostic procedures) associated with research study 
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participation; (2) addressing correct payment for tests and procedures ordered by the 
investigators; and/or (3) for internal hospital operations (i.e. quality assurance). 
We may share the research sample obtained in this study with other investigators 
interested in POF. The name of the participants, and family members enrolled, and all personal 
identifying information, such as address, social security number, and date of birth, will be 
removed.  Therefore, the Biobank will not give out your name, or other information that 
identifies you, your family member or children, to the scientists who receive the samples. 
However, the scientists will have some data about you, such as age, sex, diagnosis, race, and 
outcomes of the initial study. 
For how long will the investigators be permitted to use and disclose identifiable 
information related to my participation in this research study? 
The investigators may continue to use and disclose, for the purposes described above, 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study for a minimum of seven years after final reporting or 
publication of a project. 
 
May I have access to my medical information that results from my participation in this 
research study? 
In accordance with the UPMC Notices of Privacy Practices document that you have been 
provided, you are permitted access to information (including information resulting from your 
participation in this research study) contained within your medical records filed with your health 
care provider. 
Is my participation in this research study voluntary? 
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Your participation in this research study, to include the use and disclosure of your 
identifiable information for the purposes described above, is completely voluntary.  (Note, 
however, that if you do not provide your consent for the use and disclosure of your identifiable 
information for the purposes described above, you will not be allowed to participate in the 
research study.)  Whether or not you provide your consent for participation in this research study 
will have no effect on your current or future relationship with the University of Pittsburgh.  
Whether or not you provide your consent for participation in this research study will have no 
effect on your current or future medical care at a UPMC hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. 
Before agreeing to participate in this research study, or at any time during your study 
participation, you may discuss your care with another doctor who is not associated with this 
research study.  You are not under any obligation to participate in any research study offered by 
your doctor. 
May I withdraw, at a future date, my consent for participation in this research study? 
You may withdraw, at any time, your consent for participation in this research study, to 
include the use and disclosure of your identifiable information for the purposes described above.  
(Note, however, that if you withdraw your consent for the use and disclosure of your identifiable 
medical record information for the purposes described above, you will also be withdrawn, in 
general, from further participation in this research study.)  Any identifiable research or medical 
information recorded for, or resulting from, your participation in this research study prior to the 
date that you formally withdrew your consent may continue to be used and disclosed by the 
investigators for the purposes described above. 
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To formally withdraw your consent for participation in this research study you should 
provide a written and dated notice of this decision to the principal investigator of this research 
study at the address listed on the first page of this form. 
Your decision to withdraw your consent for participation in this research study will have 
no effect on your current or future relationship with the University of Pittsburgh.  Your decision 
to withdraw your consent for participation in this research study will have no effect on your 
current or future medical care at a UPMC hospital or affiliated health care provider or your 
current or future relationship with a health care insurance provider. 
If I agree to take part in this research study, can I be removed from the study without 
my consent? 
The investigator or sponsor may decide to stop you from taking part in this study at any 
time. You could be removed from the study for reasons related only to you or because the entire 
study is stopped. The sponsor, investigator, Food and Drug Administration, or Institutional 
Review Board may stop the study at any time. 
You may withdraw from the study at any time and you may request that your sample be 
permanently removed if it has not already been used. 
 
************************************************************************ 
VOLUNTARY CONSENT 
The above information has been explained to me and all of my current questions have 
been answered.  I understand that I am encouraged to ask questions about any aspect of this 
research study during the course of this study, and that such future questions will be answered by 
a qualified individual or by the investigator(s) listed on the first page of this consent document at 
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the telephone number(s) given. I understand that I may always request that my questions, 
concerns or complaints be addressed by a listed investigator. 
I understand that I may contact the Human Subjects Protection Advocate of the IRB 
Office, University of Pittsburgh (1-866-212-2668) to discuss problems, concerns, and questions; 
obtain information; offer input; or discuss situations that have occurred during my participation. 
By signing this form, I agree to participate in this research study.  A copy of this consent 
form will be given to me. 
 
____________________________  ____________________________ ____________ 
Participant’s Signature   Printed Name of Participant  Date 
 
CERTIFICATION of INFORMED CONSENT 
I certify that I have explained the nature and purpose of this research study to the above-
named individual(s), and I have discussed the potential benefits and possible risks of study 
participation.  Any questions the individual(s) have about this study have been answered, and we 
will always be available to address future questions as they arise. I further verify that no research 
component of this protocol was begun until after this consent form was signed.” 
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date 
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APPENDIX B 
POF QUESTIONNAIRE 
Comprehensive Questionnaire 
POF Patient 
 
Title: Genetic Basis of Female Fertility and Premature Ovarian Failure 
 
Please complete the following questionnaire to provide important information for our 
research study being conducted at the University of Pittsburgh.  Your responses will provide 
valuable information that will help with our research study.  Please be as specific as possible. All 
your responses will be kept strictly confidential.  Thank you for participating. 
I. DEMOGRAPHICS 
1.  Name:____________________________________Date:___________________ 
2. Address:__________________________________________________________ 
3. Phone____________________________________________________________ 
 Email:____________________________________________________________ 
4. Date of Birth (Month/Day/ Year): ___________________ 
II. MENSTRUAL/MEDICAL  HISTORY 
Please list the date of your last menstrual period:_________________ 
 At what age did your period start?_________________________ 
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 At what age did they stop completely?________________________ 
Do you smoke?_______If yes, how many packs per day, and for how 
long________________________________________________ 
Please list your height and weight____________________ 
Are/were your periods painful on a regular basis? 
_____________________________________________________________________ 
What is your race?________________________________ 
Describe your cycle from early age:   
Regular    Sometimes regular    Sometimes irregular     Always Irregular 
Please describe in detail:_______________________________________________ 
 _________________________________________________________________ 
How frequent were/are your cycles?   
Monthly 
Every 2-3 months 
Please explain:________________________________________________________ 
 
III. PREMATURE OVARIAN FAILURE DIAGNOSIS 
1.  How old were you when you were diagnosed with premature ovarian failure?___ 
2.  What type of provider diagnosed you?  (e.g., OB/GYN, Reproductive Endocrinologist, 
Medical Endocrinologist, Internist)___________________________ 
3.  How long had your menses stopped before you were seen by a provider and diagnosed 
with POF? _____________________________________________________ 
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4.  Did you go to several providers before the correct diagnosis was made?  How 
many?__________________________________________________________________ 
5. Do you think most providers are aware of premature ovarian failure?  Are they helpful 
with POF information including treatment options?  Please comment. 
____________________________________________________________________ 
____________________________________________________________________ 
      ____________________________________________________________________ 
6.  Have you ever been told a reason WHY you have POF?   
If yes, please explain in detail.________________________________________ 
 __________________________________________________________________ 
 __________________________________________________________________ 
7.  Which of the following symptoms related to POF did you experience? 
 ___Irregular cycles 
 ___Heavy Bleeding 
 ___Abrupt cessation of menses 
 ___Absence of menses after stopping birth control pills 
 ___Absence of menses after delivery of a baby 
 ___Hot flashes 
 ___Mood Swings 
 ___Vaginal Dryness 
 ___Painful Intercourse 
 ___Sleep Disturbances 
 ___Depression 
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 ___Night sweats 
 ___Fatigue 
 ___Anorexia 
 ___Weight Loss 
 ___Abdominal Pain 
 ___Pelvic Pain 
 ___Changes in skin pigmentation (vitiligo, premature grey hair, etc) 
9. Have you ever had symptoms of menopause for a long period of time? (hot flashes, 
mood swings, vaginal dryness, or dry skin) If so, please describe for how long: 
______________________________________________________________________________
______________________________________________________________________________
____________________________________________________________ 
List other significant symptoms related to POF not noted above:  
________________________________________________________________________ 
10.  Please indicate if you have been previously diagnosed with any of the following:  
Please note when you were diagnosed and comment if necessary. 
Endometriosis 
Pelvic inflammatory disease (PID) 
Sexually transmitted infections (ex. gonorrhea, Chlamydia, etc.)   
Thyroid Disorder  
Polycystic Ovarian Syndrome 
Uterine Fibroids  
Diabetes 
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Adrenal Disorder (Addison’s disease, Cushing’s) 
Lupus 
Autoimmune Disease 
Anorexia or Bulimia 
Galactosemia 
Cancer with chemotherapy or radiation treatment 
Grave’s Disease 
Hashimoto’s Thyroiditis 
Myasthenia Gravis 
Hypoparathyroidism 
Autoimmune polyglandular syndrome 
Fragile X Syndrome 
Turner’s syndrome 
Mumps  
Inherited Enzyme deficiency 
Inherited Syndrome-please list_____________________________________________ 
Pituitary Disorder 
Osteoporosis 
11. Have you ever been exposed to chemicals or radiation through your work or 
residence? Explain.____________________________________________________ 
12. Have you ever had a cyst or ovary removed or other surgery on your ovary (ies)? (If 
so, state year and type of surgery) 
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______________________________________________________________________________
_________________________________________________________________ 
Are both of your tubes and ovaries present?__________________________________ 
13.  Do you have a family history of POF?  If so, who also has been diagnosed with this 
disorder?  Please list (e.g., mother, sister, aunt, cousin, grandmother) 
 __________________________________________________________________ 
14.  Do any inherited diseases run in your family?  If so, please list 
 __________________________________________________________________ 
 __________________________________________________________________ 
15.  Which of the following have you had done to evaluate for POF: 
 ___Karyotype 
 ___Thyroid Tests (TSH) 
 ___Adrenal Function Tests 
 ___Diabetes Evaluation (Glucose) 
 ___Autoimmune Antibody Testing 
 ___FSH/LH Levels 
 ___Ovarian Biopsy 
 ___Pelvic Ultrasound 
16.  What abnormalities were detected at the time of your diagnosis?  Please explain in 
detail. ________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________ 
17. How often do you follow-up with your doctor since being diagnosed with POF? 
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 Annually    Every six months    As needed    No Follow-up after diagnosis 
 Other:__________________ 
IV. PREGNANCY HISTORY 
1.  How many times have you been pregnant, if applicable?________ 
2. How many live births have you had? Please list year(s) of delivery, if 
applicable___________________________________________________________ 
3. How many preterm births? Please list year(s) if applicable__________________ 
4. List the sex of your children-Males______  Females_____ 
5. How many miscarriages in the past? Please list year(s), if applicable_____ 
6. Did you ever have a genetic analysis on the tissue?  If so, what was it?  Male/Female 
or another abnormality?___________________________________ 
7. How many elective terminations (abortions)?_____ 
8. Any unusual problems during pregnancy?  (e.g., toxemia, diabetes, thyroid disease, 
liver problems, etc).  Please list.__________________________________ 
________________________________________________________________________
________________________________________________________________ 
 
V. FERTILITY CONCERNS 
1.  Since diagnosis of POF, have you ovulated on your own or while taking 
hormones?______________________________________________________ 
1b.  Does infertility run in your family? If so, please list relationship to you. Did they 
have to use fertility drugs or IVF to conceive? 
______________________________________________________________________________
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______________________________________________________________________________
_________________________________________________ 
1c.  Do you have a family history of early menopause or ovarian failure in your family? Please 
list relationship and age of menopause. _________________________ 
________________________________________________________________________ 
2.  Do you take hormonal medications now?  Please list (estrogen, progesterone, birth 
control pills)___________________________________________________ 
3.  Have you become pregnant since being diagnosed with POF?  _______________ 
 __________________________________________________________________ 
4.  Have you delivered a baby since your diagnosis?__________________ 
5.  Do you plan to use assisted reproductive technology (ART) or in-vitro fertilization 
(IVF) in attempts to conceive?__________________________________ 
 Which of the following have you considered? 
  ___Hormone Therapy (Estrogen and/or Progesterone) 
  ___Clomid 
  ___Pergonal or Gonadotropins (injectable drugs) 
  ___IVF  
   ___Own Eggs (if possible) 
   ___Donor Eggs (sister or anonymous donor) 
6. How many times have you been treated with fertility drugs in the past? Please explain 
in detail: _________________________________________________________ 
______________________________________________________________________________
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______________________________________________________________________________
___________________________________________________________ 
  
7. Have you ever been told that you do not stimulate well with fertility 
drugs?_________________________________________________________________ 
8. If you underwent IVF in the past, please list when and how many eggs were retrieved, 
if you can recall.  
______________________________________________________________________________
__________________________________________________________________ 
 
VI. HEALTH STATUS 
1. Have you had any health problems since being diagnosed with POF?  Please list and 
explain.__________________________________________________________ 
________________________________________________________________________
________________________________________________________________ 
2. Was a DEXA scan or XRAY recommended to evaluate your bones? __________ 
3. Are you aware that you are at higher risk for heart disease and osteoporosis because of 
POF?  _____________________________________________________ 
4. Did your provider discuss these potential health problems with you?__________ 
5. Where have you learned the most about your disorder? 
____Physician provider 
____Internet 
____POF Support Group in local area 
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____Medical Library 
____Research Study (please list which one) 
____Other 
VII. TREATMENT 
1. Are you taking any type of hormone replacement therapy (HRT) or Birth Control Pill 
containing hormones NOW?  Please list._______________________ 
2.  Have you been placed on any other medications to help treat your POF?  If so, please 
list. 
Androgens (i.e., Testosterone)_________________________ 
 Steroids____________________________________________ 
 Immunosuppressant therapy__________________________ 
 Others_____________________________________________ 
3.  Are you using alternative medications/therapies to treat your POF or to ovulate in 
hopes of conceiving?  Please list__________________________________________ 
4.  Were you aware that patients with POF can conceive spontaneously 5-10% of the 
time?______________________________ 
5.  Were you aware that taking hormone replacement therapy does not prevent you from 
getting pregnant even if you have been diagnosed with POF?______________ 
6.  Were you aware that the only proven method of successfully achieving a pregnancy 
with POF is oocyte donation? _______________________________ 
7.  Any comments that you would like to make: 
______________________________________________________________________________ 
End of questionnaire. Thank you for your time! 
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APPENDIX C 
IRB APPROVAL FORM 
 
University of Pittsburgh 
Institutional Review Board 
3500 Fifth 
Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
 
Memorandum 
  To: Aleksandar Rajkovic   
From:  Christopher Ryan, PhD , Vice Chair 
Date: 12/20/2012 
IRB#: REN12110250  / PRO09080427 
Subject: Genetic Basis of Female Fertility and Premature Ovarian Failure  
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Your renewal for the above referenced research study has received expedited review and 
approval from the Institutional Review Board under:  
45 CFR 46.110.(9)  
 
Please note the following information:  
Approval Date: 12/20/2012   
Expiration Date: 12/19/2013   
Please note that it is the investigator’s responsibility to report to the IRB any 
unanticipated problems involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 
CFR 56.108(b)]. Refer to the IRB Policy and Procedure Manual regarding the reporting 
requirements for unanticipated problems which include, but are not limited to, adverse events.  If 
you have any questions about this process, please contact the Adverse Events Coordinator at 
412-383-1480.  
The protocol and consent forms, along with a brief progress report must be resubmitted at 
least one month prior to the renewal date noted above as required by FWA00006790 (University 
of Pittsburgh), FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 
(Children’s Hospital of Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), 
FWA00003338 (University of Pittsburgh Medical Center Cancer Institute).  
Please be advised that your research study may be audited periodically by the 
University of Pittsburgh Research Conduct and Compliance Office.  
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